The availability of a treatment that offers the possibility of improvement and extends the life expectancy for those facing cancer provides comfort and hope to those going through this challenging time in their lives.
Cuban Medical Services offer patients combined therapies that include unique, proven-effective products developed on the Island. Among them are the therapeutic vaccines CIMAvax-EGF® and Vaxira®, as well as the monoclonal antibodies CIMAher® (Nimotuzumab) and HeberFERON®. These treatments are based on the expertise of researchers in the biotechnology sector, professionals from the National Institute of Oncology and Radiobiology (INOR) who conducted the clinical trials, and experts who apply them daily to the Cuban population, achieving excellent results.
CIMAvax-EGF® y Vaxira®: Una nueva luz para el cáncer de pulmón de células no pequeñas
Para el cáncer de pulmón de células no
pequeñas en estadios avanzados (IIIB y IV), Cuba pone a disposición tratamientos pioneros. CIMAvax-EGF® and Vaxira®: A New Hope for Non-Small Cell Lung Cancer
For advanced stages (IIIB and IV) of non-small cell lung cancer, Cuba offers pioneering treatments. One of them is the therapeutic vaccine CIMAvax-EGF®, which targets the epidermal growth factor receptor and shows remarkable tolerance, even in elderly patients.
On the other hand, Vaxira®, also aimed at combating this disease in advanced stages, shows an objective clinical response after chemotherapy treatment and presents few adverse events. Patients are required to have completed the first line of cancer treatment at least four weeks prior and be in a stable condition. The efficacy of Vaxira® is supported by evidence in controlling tumor growth.
Both therapies contribute to improving respiratory capacity, physical condition, and emotional well-being of patients. They are implemented in two stages: the first for inducing a higher dose, while the second focuses on maintenance with more spaced doses, following corresponding medical guidelines.
CIMAher®: A Breakthrough for Head and Neck Cancer
The comprehensive cancer treatment with CIMAher® offers a promising alternative for advanced-stage head and neck cancer. This monoclonal antibody has shown effective synergy with conventional therapies such as radiotherapy and chemotherapy, demonstrating positive responses in disease control. Additionally, it is used in the treatment of malignant esophageal tumors and in patients with non-small cell lung cancer.
HeberFERON®: Hope for Basal Cell Carcinoma Skin Cancer
People with basal cell carcinoma type skin cancer find hope in HeberFERON®, a medication that combines recombinant human alpha and gamma interferons. Indicated for lesions of any size and location, including high-risk areas such as the H zone of the face or locally advanced areas difficult to treat due to proximity to the eyes or brain, this monoclonal antibody induces faster therapeutic responses, prolongs treatment effects for at least five years, reduces the frequency of new lesions eightfold, and decreases tumor mass, avoiding complex surgeries and their sequelae in delicate parts of the face and body.
International Health Center, La Pradera: A Comprehensive Well-being Environment
Among the institutions supporting these programs, the International Health Center, La Pradera, in the west of the city, offers a natural environment where high-quality hotel services are combined with specialized medical care. Services include hospitalization, accommodation, meals, medical and nursing care, initial evaluation, and more, providing patients and their families with a comprehensive approach that combines scientific rigor, comfort, and the human warmth of specialists.
These highly specialized cancer treatments represent a unique opportunity that Destination Cuba offers to those seeking hope and a better quality of life. Supported by the National Health System, Cuba positions itself as a destination for those seeking innovative treatments and positive results in the fight against cancer.
To start treatment, you must contact the Coordination and Processing Center of Comercializadora de Servicios Médicos Cubanos, S.A. via email at smc@smcsalud.cu. You will be sent the medical program with its costs.
By: MSc. Dr. Patricia Alonso Galbán
Marketing and Communication Specialist, CSMC, S.A.